UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 8-K

__________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 30, 2020

__________________

EYENOVIA, INC.

(Exact name of registrant as specified in its charter)

__________________

Delaware

(State or other jurisdiction of incorporation)

Registrant's telephone number, including area code (917) 289-1117

__________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this Chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

(e)           At the 2020 annual meeting of stockholders (the “Annual Meeting”) of Eyenovia, Inc. (the “Company”), stockholders approved a proposal for the Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan (the “Amended and Restated Plan”). The Amended and Restated Plan (i) increases the total number of shares of common stock reserved for issuance under the Amended and Restated Plan to 2,950,000 shares; (ii) adds provisions which require that all equity awards granted under the Amended and Restated Plan will vest at least twelve months from the applicable grant date, subject to accelerated vesting; (iii) adds provisions which provide that no dividend or dividend equivalent will be paid on any unvested equity award, although dividends with respect to unvested portions of equity awards may accrue and be paid when and if the awards later vest and shares are actually issued to the grantee; (iv) eliminates or amends certain provisions to reflect changes in Section 162(m) of the Internal Revenue Code; and (v) makes other administrative changes. The Company’s Board of Directors (the “Board”) approved the Amended and Restated Plan on April 7, 2020, subject to stockholder approval.

You can find a summary of the principal features of the Amended and Restated Plan in the definitive proxy statement for the Annual Meeting, filed with the SEC on April 29, 2020 (the “2020 Proxy Statement”), under the heading “Proposal Two – Approval of the Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan”. The summary of the Amended and Restated Plan contained in the 2020 Proxy Statement is qualified in its entirety by the full text of the Amended and Restated Plan filed as Exhibit 10.25 to this Current Report on Form 8-K.

The Company convened and then immediately adjourned its Annual Meeting on June 11, 2020 to June 30, 2020. At the Annual Meeting on June 30, 2020, stockholders approved the following proposals:

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.